Navigation Links
DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Date:7/30/2008

CUPERTINO, Calif., July 30 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2008 financial results press release, you are invited to listen to the conference call that will be broadcast live over the Internet on Wednesday, August 6, 2008 at 9:00 a.m. EDT (6:00 a.m. PDT).

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including Remoxy(TM), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. Remoxy, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
2. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
3. DURECT to Participate in Morgan Stanley Global Healthcare Conference
4. DURECT Provides Update on CHRONOGESIC(R) Research Program
5. DURECT to Participate in Cowen Annual Healthcare Conference
6. DURECT to Participate in Susquehanna Financial Healthcare Conference
7. DURECT to Present at BIO CEO Investor Conference 2008
8. DURECT to Present at 2007 BIO Investor Forum
9. DURECT to Present at UBS Global Life Sciences Conference
10. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
11. STERIS Corporation Announces Fiscal 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , ... September 22, 2017 , ... Happy Living’s mission ... time - carries it into the entertaining and delicious worlds of theatre and ... (founder of Happy Living) convinced him to turn his play into a book. The ...
(Date:9/22/2017)... ... 22, 2017 , ... TopConsumerReviews.com recently awarded their highest five-star ... promote pancreatic health and regulate blood sugar levels . , Preventing diabetes ... negative side effects, and with the changes in today’s healthcare industry, not everyone ...
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... The freshly released ... doorstep. According to Smart Mart, customers can now order vegetable, fruit, snacks, dairy, ... customers can find clothing at discounted prices. Apart from this, Smart Mart has ...
(Date:9/21/2017)... Viejo, CA (PRWEB) , ... September 21, 2017 , ... ... been so fun and easy to do. Users can select from up to two ... all with a click of a mouse all within Final Cut Pro X. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and ... primary and secondary endpoint data for lasmiditan, an investigational, ... which demonstrated statistically significant improvements compared to placebo in ... highlighted today at the 18th Congress of the International ... "The data presented today demonstrate lasmiditan,s potential ...
Breaking Medicine Technology: